Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Asl 8052
2. Asl-8052
3. Brevibloc
4. Esmolol
1. 81161-17-3
2. Esmolol Hcl
3. Brevibloc
4. Esmolol (hydrochloride)
5. Asl-8052
6. Esmolol Hydrochloride [usan]
7. Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate;hydrochloride
8. Asl8052
9. V05260lc8d
10. Dsstox_cid_28929
11. Dsstox_rid_83195
12. Dsstox_gsid_49003
13. Benzenepropanoic Acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, Methyl Ester, Hydrochloride
14. Asl 8052
15. (+-)-methyl P-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate Hydrochloride
16. 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoic Acid Methyl Ester Hcl
17. Chebi:4857
18. Cas-81161-17-3
19. Hsdb 6530
20. Ncgc00185766-01
21. Brevibloc In Plastic Container
22. Unii-v05260lc8d
23. Sr-01000763706
24. Methyl 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoate Hydrochloride
25. Methyl 3-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}propanoate Hydrochloride
26. Brevibloc (tn)
27. Clol
28. Brevibloc Double Strength In Plastic Container
29. Schembl41086
30. Esmolol Hydrochloride- Bio-x
31. Mls001401393
32. Chembl1201115
33. Dtxsid7049003
34. Esmolol Hydrochloride (jan/usp)
35. Esmolol Hydrochloride [mi]
36. Esmolol Hydrochloride [jan]
37. Bcp28434
38. Hy-b1392
39. Esmolol Hydrochloride [hsdb]
40. Tox21_113496
41. Esmolol Hydrochloride [vandf]
42. Mfcd00941432
43. S4100
44. Esmolol Hydrochloride [mart.]
45. Akos015895316
46. Esmolol Hydrochloride [usp-rs]
47. Esmolol Hydrochloride [who-dd]
48. Tox21_113496_1
49. Ab07716
50. Ac-6972
51. Ccg-100972
52. Ccg-220890
53. Cs-4908
54. Ks-1353
55. Nc00222
56. Ncgc00185766-04
57. Be164425
58. Benzenepropanoic Acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, Methyl Ester, Hydrochloride, (+-)-
59. Smr000469141
60. Esmolol Hydrochloride [orange Book]
61. Esmolol Hydrochloride [usp Monograph]
62. Ft-0601541
63. Ft-0667970
64. Ft-0667971
65. Sw197602-3
66. D00644
67. Esmolol Hydrochloride, >=98% (hplc), Solid
68. F20655
69. 1-(3-methylphenyl)piperazinedihydrochloridehydrate
70. 598e034
71. 81161-17-3, 81147-92-4(free Base)
72. J-003862
73. Q-201070
74. Sr-01000763706-4
75. Q27106523
76. Esmolol Hcl; Brevibloc; Asl-8052; Asl 8052; Asl 805
77. Esmolol Hydrochloride, United States Pharmacopeia (usp) Reference Standard
78. (+/-)-methyl P-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate Hydrochloride
79. (+/-)-methyl P-[2-hydroxy-3-(isopropylamino) Propoxy]hydrocinnamate Hydrochloride
80. Methyl 3-{4-[2-hydroxy-3-(isopropylamino)propoxy]-phenyl}propanoate Hydrochloride
81. Benzenepropanoic Acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, Methyl Ester, Hydrochloride (1:1)
82. Benzenepropanoic Acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, Methyl Ester, Hydrochloride, (+/-)-
83. Methyl 3-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}propanoate Hydrochloride (esmolol Hcl)
| Molecular Weight | 331.8 g/mol |
|---|---|
| Molecular Formula | C16H26ClNO4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 10 |
| Exact Mass | 331.1550360 g/mol |
| Monoisotopic Mass | 331.1550360 g/mol |
| Topological Polar Surface Area | 67.8 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 288 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 8 | |
|---|---|
| Drug Name | Brevibloc |
| PubMed Health | Esmolol (Injection) |
| Drug Classes | Antiarrhythmic, Group II, Cardiovascular Agent |
| Drug Label | BREVIBLOC (Esmolol Hydrochloride) is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:()-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnam... |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 2 of 8 | |
|---|---|
| Drug Name | Brevibloc double strength in plastic container |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 2gm/100ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 3 of 8 | |
|---|---|
| Drug Name | Brevibloc in plastic container |
| Drug Label | Esmolol hydrochloride is a beta1-selective (cardioselective) adrenergic receptor blocking agent with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:()-Methyl p-[2-hydroxy-3-(isopropylami... |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1gm/100ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 4 of 8 | |
|---|---|
| Drug Name | Esmolol hydrochloride |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 2000mg/100ml (20mg/ml); 2500mg/250ml (10mg/ml); 10mg/ml |
| Market Status | Tentative Approval; Prescription |
| Company | Fresenius Kabi Usa; Hq Speciality Pharma; Mylan Institutional; Eurohlth Intl |
| 5 of 8 | |
|---|---|
| Drug Name | Brevibloc |
| PubMed Health | Esmolol (Injection) |
| Drug Classes | Antiarrhythmic, Group II, Cardiovascular Agent |
| Drug Label | BREVIBLOC (Esmolol Hydrochloride) is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:()-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnam... |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 6 of 8 | |
|---|---|
| Drug Name | Brevibloc double strength in plastic container |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 2gm/100ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 7 of 8 | |
|---|---|
| Drug Name | Brevibloc in plastic container |
| Drug Label | Esmolol hydrochloride is a beta1-selective (cardioselective) adrenergic receptor blocking agent with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:()-Methyl p-[2-hydroxy-3-(isopropylami... |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1gm/100ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 8 of 8 | |
|---|---|
| Drug Name | Esmolol hydrochloride |
| Active Ingredient | Esmolol hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 2000mg/100ml (20mg/ml); 2500mg/250ml (10mg/ml); 10mg/ml |
| Market Status | Tentative Approval; Prescription |
| Company | Fresenius Kabi Usa; Hq Speciality Pharma; Mylan Institutional; Eurohlth Intl |
Adrenergic Beta-Antagonists
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Esmolol is used IV principally to provide rapid, temporary control of ventricular rate in patients with supraventricular tachyarrhythmias (SVT) (eg, atrial flutter and/or fibrillation, sinus tachycardia).
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1748
Esmolol may be preferred to longer-acting B-adrenergic blocking agents for the short-term control of ventricular rate in patients with SVT because of the drug's rapid onset and short duration of effects, ... .
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1748
Esmolol is indicated for rapid and short-term control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergency situations. It is also indicated in noncompensatory sinus tachycardia judged by the physician to need intervention. (Esmolol is used for control of heart rate in patients with myocardial ischemia. /NOT included in US product labeling/) It is not recommended for use in chronic situations where transfer to another agent is anticipated. /Included in US product labeling/
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1231
For more Therapeutic Uses (Complete) data for ESMOLOL HYDROCHLORIDE (6 total), please visit the HSDB record page.
Because of the risk of esmolol induced hypotension, blood pressure should be monitored closely during therapy with this drug, especially in patients with low pretreatment blood pressure (eg, systolic blood pressure less than 105 mm Hg). Hypotension can occur at any dose level with esmolol but usually is dose related, and doses exceeding 200 ug/kg per minute recommended by the manufacturer for the management of supraventricular tachyarrhythmias. Reversal of hypotension usually occurs within 30 minutes of discontinuing the drug or reducing the rate of IV infusion.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1751
... Esmolol is contraindicated in patients with second- or third-degree atrioventricular blocks, sinus bradycardia, cardiogenic shock, or overt cardiac failure.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1751
Esmolol may mask signs and symptoms of hypoglycemia (eg, tachycardia, palpitation, blood pressure changes, tremor, feelings of anxiety, but not sweating or dizziness) and may potentiate insulin-induced hypoglycemia; therefore, the drug should be used with caution in patients with diabetes mellitus or hypoglycemia.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1751
Because of de-esterified metabolite (ASL 8123) of esmolol is eliminated mainly by the kidneys, ... the drug should be used with caution in patients with renal impairment, especially severe impairment.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1751
For more Drug Warnings (Complete) data for ESMOLOL HYDROCHLORIDE (16 total), please visit the HSDB record page.
Adrenergic beta-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)
It is not known whether esmolol and/or ASL 8123 cross the placenta in humans, but the drug has been shown to cross the placenta in animals. In animals, fetal artery esmolol concentrations were about 10% of maternal concentrations at the completion of infusion. It also is not known whether esmolol and/or ASL 8123 are distributed into milk.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
Following IV administration, esmolol is rapidly and widely distributed. The apparent volumes of distribution of esmolol and its de-esterifed metabolite (ASL 8123) in healthy adults are approximately 3.4 and 0.41 l/kg, respectively, following iv administration. In healthy adults, the volumes of distribution of esmolol in the central compartment and at steady state are approximately 0.87 and 1.2 l/kg, respectively, following IV administration. The apparent volume of distribution appears to be decreased in patients undergoing coronary artery bypass surgery and increased in patients with renal impairment undergoing peritoneal dialysis and in patients with liver cirrhosis.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
Following IV administration in rats, esmolol is ditributed into liver and kidneys, but only minimally into CSF, spleen, or testes.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
In vitro, esmolol is approximately 55% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein. Protein binding of esmolol to alpha-1-acid glycoprotein does not appear to be concentration dependent at esmolol concentrations of 3-110 ug/ml. In vitro, ASL 8123 is approximately 10% bound to plasma proteins.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
For more Absorption, Distribution and Excretion (Complete) data for ESMOLOL HYDROCHLORIDE (10 total), please visit the HSDB record page.
Esmolol is rapidly and extensively metabolized via esterases (probably arylesterase), principally in the cytosol of erythrocytes. Metabolism of the drug also may occur in highly perfused tissues that contain esterases (eg, liver, kidneys). Hydrolysis of the methyl ester moiety results in formation of the de-esterified (free acid) metabolite, 4-(2-hydroxy-3-((1-methylethyl)amino) propoxy)benzenepropanoic acid (ASL 8123), and methanol. Esmolol does not appear to be susceptible to hydrolysis via serum cholinesterase (pseudocholinesterase), acetylcholinesterase, or carbonic anhydrase. It is estimated that about 83% of an esmolol dose is metabolized to ASL 8123. ASL 8123 has a low affinity for beta-adrenergic receptors, exhibiting only minimal (about 1,000- to 1,500-fold less potent than esmolol) beta-blocking activity in animals and no appreciable blockade in humans. Unlike esmolol, ASL 8123 is eliminated principally by the kidneys, and the elimination half-life of the metabolite may be increased up to tenfold in patients with renal impairment; however, such accumulation is not thought to be clinically important since ASL 8123 has only minimal beta-blocking activity. The amount of methanol formed during hydrolysis of the drug does not appear to be clinically important. Following IV infusion of esmolol hydrochloride doses of 300 ug/kg per minute for up to l6 hours of 150 ug/kg per minute for 24 hours, blood methanol concentrations ranged from 2.8-5.9 or 2.9-13.2 ug/ml, respectively, being less than 2% of those usually associated with methanol toxicity.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
Following IV infusion in adults, the half life of esmolol averages about 2 minutes in the initial distribution phase and about 9 minutes (range: 5-23 minutes) in the terminal elimination phase, although considerable interindividual variation in blood elimination half life exists.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
Free acid metabolite: approx 3.7 hr (increased up to tenfold in renal failure)
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1231
Esmolol selectively inhibits response to adrenergic stimuli by competitively blocking cardiac B1-adrenergic receptors, while having little effect on the B2-adrenergic receptors of bronchial and vascular smooth muscle. At high doses (e.g., greater than 300 ug/kg per minute), this selectivity of esmolol for B1-adrenergic receptors usually diminishes, and the drug will competitively inhibit B1-and B2-adrenergic receptors.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1752
By inhibiting myocardial beta1-adrenergic receptors, esmolol produces negative chronotropic and inotropic activity. Through its myocardial B1-adrenergic blocking action, esmolol decreases resting and exercise-induced heart rate, reflex orthostatic tachycardia, myocardial contractility, rate of left ventricular pressure rise (dp/dt), right ventricular contractility, and cardiac index.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1752
The decrease in myocardial contractility, arterial pressure, and heart rate produced by esmolol can lead to a reduction in myocardial oxygen consumption, which may account for the effectiveness of the drug in myocardial ischemia.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1753
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
About the Company : MINAKEM is a cGMP custom manufacturer specializing in small molecule APIs, HPAPIs, and steroids. Its highly skilled R&D teams, supported by strong analytical and regulatory service...
About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...
About the Company : Minakem Montreal is developing and manufacturing small molecules APIs and advanced intermediates, including corticosteroids. Following efficient processes and methodologies, our em...
About the Company : As an EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979 as Calcium Ind...

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

About the Company : Mehta API Pvt Ltd engaged in manufacturing and marketing of APIs & Advance Drug Intermediates.... Globally. Mehta Api has been inordinately proud of its achievements since its ince...

About the Company : Sailong Pharmaceutical Group Co., Ltd. ("Salon Pharmaceutical" for short) was established in 2002. It is a high-tech enterprise integrating drug research and development, productio...

About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Esmolol HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Podiatry Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Podiatry
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers
Details : Esmolol HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhagic Stroke.
Lead Product(s): Esmolol Hydrochloride,Sodium Nitroprusside
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Esmolol Hydrochloride,Sodium Nitroprusside
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhagic Stroke.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2018

Details:
Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Beth Israel Deaconess Medical Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2016

Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Beth Israel Deaconess Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia
Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2016

Details:
Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2014

Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2014

Details:
Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2014

Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol Effects on Heart and Inflammation in Septic Shock
Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2014

Details:
Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vascular Diseases.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2011

Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol
Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2011

Details:
Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2010

Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Esmolol for Treatment of Perioperative Tachycardia
Details : Esmolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Esmolol HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.
Lead Product(s): Esmolol Hydrochloride,Inapplicable
Therapeutic Area: Podiatry Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Esmolol Hydrochloride,Inapplicable
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
Details : Esmolol HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 30, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies

13 Dec 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216603

02 Dec 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214172

21 Mar 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216244

19 Aug 2019
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208538

13 Sep 2018
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mylan-adds-to-cardiovascular-portfolio-with-launch-of-first-generic-of-brevibloc-injection-in-single-dose-bags-300712105.html

12 Jun 2018
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207107
Global Sales Information
Market Place
Reply
17 Dec 2024
Reply
20 Feb 2023
Reply
01 Jul 2021
Reply
24 Mar 2021
Reply
26 Feb 2021
Reply
11 Apr 2019
Reply
16 Mar 2019
Reply
14 Dec 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
100
PharmaCompass offers a list of Esmolol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Esmolol Hydrochloride manufacturer or Esmolol Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Esmolol Hydrochloride manufacturer or Esmolol Hydrochloride supplier.
PharmaCompass also assists you with knowing the Esmolol Hydrochloride API Price utilized in the formulation of products. Esmolol Hydrochloride API Price is not always fixed or binding as the Esmolol Hydrochloride Price is obtained through a variety of data sources. The Esmolol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Esmolol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Esmolol, including repackagers and relabelers. The FDA regulates Esmolol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Esmolol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Esmolol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Esmolol supplier is an individual or a company that provides Esmolol active pharmaceutical ingredient (API) or Esmolol finished formulations upon request. The Esmolol suppliers may include Esmolol API manufacturers, exporters, distributors and traders.
click here to find a list of Esmolol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Esmolol DMF (Drug Master File) is a document detailing the whole manufacturing process of Esmolol active pharmaceutical ingredient (API) in detail. Different forms of Esmolol DMFs exist exist since differing nations have different regulations, such as Esmolol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Esmolol DMF submitted to regulatory agencies in the US is known as a USDMF. Esmolol USDMF includes data on Esmolol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Esmolol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Esmolol suppliers with USDMF on PharmaCompass.
A Esmolol written confirmation (Esmolol WC) is an official document issued by a regulatory agency to a Esmolol manufacturer, verifying that the manufacturing facility of a Esmolol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Esmolol APIs or Esmolol finished pharmaceutical products to another nation, regulatory agencies frequently require a Esmolol WC (written confirmation) as part of the regulatory process.
click here to find a list of Esmolol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Esmolol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Esmolol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Esmolol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Esmolol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Esmolol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Esmolol suppliers with NDC on PharmaCompass.
Esmolol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Esmolol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Esmolol GMP manufacturer or Esmolol GMP API supplier for your needs.
A Esmolol CoA (Certificate of Analysis) is a formal document that attests to Esmolol's compliance with Esmolol specifications and serves as a tool for batch-level quality control.
Esmolol CoA mostly includes findings from lab analyses of a specific batch. For each Esmolol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Esmolol may be tested according to a variety of international standards, such as European Pharmacopoeia (Esmolol EP), Esmolol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Esmolol USP).